The OCMX™ is pleased to announce the listing of IoTech International, Inc to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

BOCA RATON, FL, November 15, 2018 /24-7PressRelease/ — ioTech’s patented, next-generation, antimicrobial technology provides superior germ-killing products for massive global markets across multiple industries. Initial focus is on the professional dental market in the U.S. and Canada for the prevention and treatment of periodontal disease. Products are sold direct to dentists (for resale to patients) and direct to dental patients. Global rollout to follow.

ioTech has harnessed the power of molecular iodine (the only biocidal or germ-killing species of iodine), boosting its strength to 150 times greater availability than possible with commonly available povidone iodine.

Simultaneously, the Company’s patented technology suppresses all other non-biocidal forms of iodine to negligible levels. The resulting stable formulations are non-staining, do not sting or burn and are a generational advance over existing technology. With unprecedented levels of safety and effectiveness, they are rapidly effective against all classes of microorganisms (bacteria, viruses, fungi and spores). They also prevent the development of bacterial resistance, a major drawback of antibiotics and most other antimicrobials, rendering them useless with over-use.

The OCMX™ is pleased to announce the listing of IoTech International, Inc to its online portal which offers Investors and Advisors the ability to participate in this opportunity.

The OCMX™ has spent considerable time completing its due diligence on IoTech International, Inc and concluded that there is indeed a tremendous opportunity for Investors and Advisors.

The OCMX™ noted that IoTech International, Inc exhibits the main components of any solid investment opportunity, namely a solid management team, a great track record, and a number of key competitive advantages.


Herb Moskowitz, D.D.S., Chairman, CEO and Co-Founder

Dr. Moskowitz has 40 years of healthcare experience, including 23 years in the clinical practice of dentistry. He is the principal shareholder and co-author of ioTech’s core patent application.

He has co-founded and served as Chairman and Chief Executive Officer of two publicly-traded medical technology companies as well as a Board Member to five. Dr. Moskowitz has also provided venture capital and guidance to launch additional technology companies.

Edward J. Quilty, Director, CEO (designate)

Mr. Quilty has an extensive and distinguished history with start-ups and has been responsible for the successful introduction of numerous, innovative, medical products. He has served as Chairman and Chief Executive Officer of five public and private medical technology companies over the last 20 years, including Derma Sciences, MedChem Products, and Palatin Technologies. Mr. Quilty has led financing and M&A transactions approaching $2 billion during that period.

Jack Kessler, Ph.D., Chief Scientist, Co-Founder, Chairman, Scientific Advisory Board

Dr. Kessler’s previous experience includes Manager, Research and Development, Amoco Biotechnology; Senior Scientist, New Technology Evaluation, Hoffman La Roche; Founder, Chairman and Chief Scientific Officer, Symbollon Corp.; Co-Founder, Chief Scientific Officer, Director of R&D for ioTech International.

He is the holder of 22 U.S. patents, co-authored ioTech’s patent applications, authored a textbook chapter on Iodine, and dozens of other articles in peer-reviewed scientific publications.

Jay Chung, J.D. Executive V.P., Legal and Financial, Director

Mr. Chung is the current V.P. and CFO of a leading regional management company. He is a seasoned attorney with an emphasis on International Law and strong background in economics, business development and finance.

Scientific Advisory Board

Includes the Deans of two U.S Dental Schools, The President of the American Academy of Otolaryngology, an Internationally acclaimed Professor of Periodontics and the President of the Society of Oral Implantologists and a Pioneer in iodine chemistry.


The OCMX™ is literally changing how companies and investment funds generate exposure in the marketplace and raise funds as we know it. The OCMX™ serves both public and private companies along with investment and mutual funds which need to raise additional funds or gain significant market exposure. It does this by way of connecting the relevant companies, funds, investors, and advisors all in one online transparent portal. The OCMX™ (P2P Financial Inc.) launched in September of 2009 out of Toronto but has since expanded its operations to include Quebec, Alberta, Manitoba, and British Columbia.

The OCMX™ connects investors and advisors directly with companies and investment funds seeking to raise funds or gain broad market exposure. The OCMX™ provides an open venue for innovative growth companies and leading investment funds to generate market awareness, raise funds, or connect with investors and advisors. The OCMX™ provides companies, funds, investors, and advisors instant access to its Online Portal so that they can actively source and connect with their next opportunity, advisor, investor, client, or financing partner.

Contact Us
TD Canada Trust Tower
161 Bay Street, 45th Floor
Toronto, Ontario, M5J 2S1
Tel: 1-866-209-6862
Email: [email protected]

For the original version of this press release, please visit here